Piper Sandler Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)

In a report released today, Biren Amin from Piper Sandler maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $28.00. The company’s shares closed last Friday at $23.80.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Amin covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Sarepta Therapeutics, and Viking Therapeutics. According to TipRanks, Amin has an average return of 3.4% and a 46.47% success rate on recommended stocks.

In addition to Piper Sandler, Apellis Pharmaceuticals also received a Hold from TR | OpenAI – 4o’s Dex Genotek in a report issued on October 4. However, on September 29, H.C. Wainwright reiterated a Buy rating on Apellis Pharmaceuticals (NASDAQ: APLS).

The company has a one-year high of $35.72 and a one-year low of $16.10. Currently, Apellis Pharmaceuticals has an average volume of 2.44M.

Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of APLS in relation to earlier this year. Last month, James George Chopas, the VP of APLS sold 189.00 shares for a total of $4,571.91.